|
The "Why" and "How" of eCTD Conversions
Gina Ross
Director, Managing Consultant
Regulatory
Publishing Services
Beckloff Associates
a Cardinal Health Company
Recording
US$249
|
 |
Purchase
a recording of this Audio Conference
Effective
January 1, 2008, all electronic submissions submitted to FDA in
the United States must be in eCTD format. This deadline is forcing
organizations within the pharmaceutical industry to evaluate the
transition from submitting paper documents to submitting electronic
documents to global regulatory agencies. The transition from paper
documents to electronic documents encompasses many areas within
an organization and integrates technology with regulatory requirements
for submission and regulatory document preparation. This presentation
will highlight the things sponsors, CROs, testing facilities,
and medical writers need to know about the impact of the eCTD
on the industry and on their businesses.
This audio
conference will address:
-
The
concept of the Common Technical Document (CTD)
-
The concept of the electronic Common Technical Document (eCTD)
-
The process for submitting regulatory applications in eCTD
format
-
How to decide if the eCTD is right for your company
-
Implementing in-house solutions vs. outsourcing eCTD preparation
Speaker
biography:
Gina A. Ross
has been involved in the pharmaceutical industry for over nine
years, and for most of that time has managed the document preparation
department for Beckloff Associates, Inc. (BAI), a pharmaceutical
research and scientific consulting firm. She was instrumental
in implementing the Common Technical Document (CTD) format in
her own organization. Beginning in August 2000, she began researching
how to implement electronic document management and electronic
submission capabilities within BAI. In 2002, she identified an
electronic document management system and actively participated
in the validation and implementation. BAI submitted its first
electronic submission in December 2004. Since that time, Gina
has overseen the submission of multiple electronic submissions,
including original submissions, amendments, annual reports, and
supplements, and the implementation and validation of eCTD software.
Recently, she has managed the submission of several original eCTDs
to the Office of Generic Drugs (OGD) and to various divisions
within FDA. She has also given numerous presentations on CTD and
eCTD implementation.
Who Should
Attend?
- Regulatory
Affairs
- Medical
and Scientific Writers
- Document
Management
- Document
Publishers
- Quality
Reviewers
- IT Personnel
- Regulatory
Submissions
This
audio conference is rated General Interest.
Purchase
Options:
|